K
KLTOW
OtherKlotho Neurosciences Inc Wt Exp
—PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving KLTOW Today?
No stock-specific AI insight has been generated for KLTOW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
KLTOW News
19 articles- Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' AwardYahoo Finance·Nov 7, 2025
- Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in BostonYahoo Finance·Oct 16, 2025
- Klotho Neurosciences Announces Expiration of Letter of IntentYahoo Finance·Oct 7, 2025
- Klotho to acquire Turn Biotechnologies’ assetsPharmaceutical-technology·Oct 1, 2025
- Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma PartnershipYahoo Finance·Sep 30, 2025
- Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific SeminarYahoo Finance·Sep 8, 2025
- Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease MarketYahoo Finance·Aug 18, 2025
- Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform TechnologyYahoo Finance·Aug 12, 2025
- UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyYahoo Finance·Jul 26, 2025
- Klotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyYahoo Finance·Jul 24, 2025
- Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy AssetsYahoo Finance·Jul 22, 2025
- Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity RulesYahoo Finance·Jul 16, 2025
- Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")Yahoo Finance·Jul 10, 2025
- Klotho Neurosciences Begins Manufacture, Prep Work Ahead of Clinical Trials of Potential Sclerosis TherapyYahoo Finance·Jun 30, 2025
- Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALSYahoo Finance·Jun 30, 2025
- Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived PopulationYahoo Finance·Jun 24, 2025
- KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMSYahoo Finance·Jun 18, 2025
- KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENTYahoo Finance·Jun 16, 2025
- KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")Yahoo Finance·Jun 9, 2025
All 19 articles loaded
Price Data
Open—
Previous Close—
Day High—
Day Low—
52 Week High—
52 Week Low—
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
About Klotho Neurosciences Inc Wt Exp
Klotho Neurosciences Inc Wt Exp (KLTOW) · Other
Listed September 17, 2024
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—